Back

Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity and protection: from bench to bedside Lipid-Lowering Agents Open Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Klaus G Parhofer

Ludwig Maximilians University, Munich (Germany)

6 More presentations in this session

Presentation thumbnail
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM
Professor A. Wang (Durham, US)
Abstract Slides Video
Presentation thumbnail
A UK multicentre experience of osimertinib related cardiovascular toxicity: real world patterns, risk stratification and surveillance
Doctor C. Simela (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on cardiac remodeling and sirtuin expression in rats with type 1 diabetes mellitus
Associate Professor M. Okoshi (Botucatu, BR) Miss A. Marreiros (Botucatu, BR)
Abstract Slides Video
Presentation thumbnail
Maternal fluconazole use during the third trimester and risk of QT prolongation in the offspring
Doctor G. Ninh (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study
Professor P. Liu (Tainan, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity and protection: from bench to bedside

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Session
Late-breaking science on pharmacology
thumbnail
Congress Presentation
Ongoing research and hope for patients with elevated Lp(a)
thumbnail
Congress Session
Late-Breaking Clinical Science: lipids and cardiovascular risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources